Checkpoint Therapeutics, Inc., a subsidiary of Fortress Biotech, Inc., has made significant strides in the acquisition, development, and commercialization of novel treatments for solid tumor cancers. With a focus on clinical-stage immunotherapy and targeted oncology, the company's lead product candidate is Cosibelimab, a fully-human monoclonal antibody that directly binds to programmed death ligand-1 (PD-L1), blocking its interaction with programmed death receptor-1 and B7.1 receptors. The company is also developing CK-302, a human agonistic antibody that aims to trigger GITR expressing cells, and Olafertinib, a promising third-generation epidermal growth factor receptor (EGFR) inhibitor for treating patients with EGFR mutation-positive non-small cell lung cancer. Moreover, Checkpoint Therapeutics, Inc. is working on CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains, and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody that identifies and kills CAIX expressing cells via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Collaborating with TG Therapeutics, Inc., the company intends to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. Checkpoint Therapeutics, Inc. was incorporated in 2014 and is based in Waltham, Massachusetts.
Checkpoint Therapeutics, Inc.'s ticker is CKPT
The company's shares trade on the NASDAQ stock exchange
They are based in New York City, New York
There are 1-10 employees working at Checkpoint Therapeutics, Inc.
It is http://checkpointtx.com/
Checkpoint Therapeutics, Inc. is in the Healthcare sector
Checkpoint Therapeutics, Inc. is in the Biotechnology industry
The following five companies are Checkpoint Therapeutics, Inc.'s industry peers: